• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Sotera Health Company

    8/22/25 10:46:18 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001599220
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Sotera Health Co
    SEC File Number
    001-39729
    Address of Issuer
    9100 SOUTH HILLS BLVD, SUITE 300
    BROADVIEW HEIGHTS
    OHIO
    44147
    Phone
    440-262-1410
    Name of Person for Whose Account the Securities are To Be Sold
    Rutz Michael P
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Charles Schwab & Co.
    3000 Schwab Way
    Westlake � TX � 76262
    1266112040969.0028404660608/22/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock11/20/2020Equity CompensationIssuerCheckbox not checked12661111/20/2020Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Shares to be sold were shares granted as apart of equity compensation between 11/20/20-3/2/25
    Date of Notice
    08/22/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Michael Rutz

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    SEC Filings

    View All

    SEC Form 144 filed by Sotera Health Company

    144 - Sotera Health Co (0001822479) (Subject)

    8/22/25 10:46:18 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Sotera Health Company

    10-Q - Sotera Health Co (0001822479) (Filer)

    8/8/25 4:19:13 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sotera Health Co (0001822479) (Filer)

    8/8/25 7:44:28 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports First-Quarter 2025 Results

    Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

    5/1/25 7:38:53 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health upgraded by Goldman with a new price target

    Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

    5/5/25 8:27:32 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Goldman initiated coverage on Sotera Health with a new price target

    Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

    12/6/24 8:14:45 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Piper Sandler initiated coverage on Sotera Health with a new price target

    Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

    5/21/24 7:45:20 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,508 shares, decreasing direct ownership by 6% to 189,602 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    8/7/25 6:09:02 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Flynn Karen was granted 19,132 shares, increasing direct ownership by 95% to 39,221 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/25 4:49:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Knauss Robert Brown was granted 19,132 shares, increasing direct ownership by 53% to 54,933 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/25 4:48:11 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports First-Quarter 2025 Results

    Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

    5/1/25 7:38:53 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care